Natera, Inc. (NASDAQ:NTRA – Get Free Report) Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the sale, the director owned 4,250 shares in the company, valued at $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Natera Stock Performance
Natera stock traded up $1.17 during mid-day trading on Friday, reaching $261.91. The company’s stock had a trading volume of 3,411,707 shares, compared to its average volume of 1,476,758. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $271.47. The company has a market capitalization of $37.51 billion, a P/E ratio of -160.68 and a beta of 1.56. The firm’s fifty day moving average price is $212.73 and its two-hundred day moving average price is $215.87.
Analyst Upgrades and Downgrades
NTRA has been the topic of a number of recent research reports. Barclays dropped their price objective on Natera from $280.00 to $260.00 and set an “overweight” rating on the stock in a report on Wednesday. Robert W. Baird set a $265.00 price target on Natera in a research report on Friday, May 8th. William Blair started coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Morgan Stanley cut their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research report on Tuesday, March 3rd. Finally, UBS Group set a $260.00 target price on shares of Natera in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $259.22.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of NTRA. Reflection Asset Management bought a new position in shares of Natera in the fourth quarter worth approximately $29,000. Palladiem LLC purchased a new position in Natera in the 4th quarter worth approximately $31,000. Bank of Jackson Hole Trust increased its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after buying an additional 83 shares during the last quarter. International Assets Investment Management LLC grew its position in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after acquiring an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new position in shares of Natera in the 4th quarter worth about $39,000. Hedge funds and other institutional investors own 99.90% of the company’s stock.
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
- Five stocks we like better than Natera
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
